Preclinical studies identifying carboplatin as a viable cisplatin alternative.

The claims of eight cisplatin analogues as viable alternatives to the parent drug are discussed in terms of their toxicities, antitumour properties and potential biochemical selectivities. It is concluded that, of the eight, diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin, CBDCA, JM8) had the features most desirable to merit its clinical evaluation.